Speciality Medicines Ltd
Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals.[1]
- Market Cap ₹ 193 Cr.
- Current Price ₹ 220
- High / Low ₹ 381 / 121
- Stock P/E 14.8
- Book Value ₹ 81.0
- Dividend Yield 0.00 %
- ROCE 25.3 %
- ROE 25.6 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 29.2%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Tax rate seems low
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 40 | 23 | 28 | 58 | 75 | |
| 38 | 20 | 22 | 49 | 62 | |
| Operating Profit | 2 | 4 | 5 | 9 | 14 |
| OPM % | 6% | 15% | 19% | 16% | 18% |
| 0 | 0 | 0 | 0 | 1 | |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 3 | 5 | 9 | 13 |
| Tax % | 31% | 43% | 36% | 1% | -0% |
| 1 | 2 | 3 | 9 | 13 | |
| EPS in Rs | 70.48 | 4.42 | 5.73 | 13.38 | 14.83 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 48% |
| TTM: | 29% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 98% |
| TTM: | 51% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | 29% |
| Last Year: | 26% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.21 | 4 | 5 | 6 | 9 |
| Reserves | 2 | 2 | 10 | 24 | 62 |
| 1 | 4 | 3 | 5 | 7 | |
| 3 | 4 | 5 | 5 | 17 | |
| Total Liabilities | 6 | 13 | 23 | 40 | 95 |
| 2 | 2 | 1 | 2 | 2 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 4 | 11 | 21 | 38 | 93 | |
| Total Assets | 6 | 13 | 23 | 40 | 95 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 1 | -4 | -5 | -6 | -1 | |
| -2 | 0 | -0 | -2 | -3 | |
| 2 | 4 | 5 | 8 | 28 | |
| Net Cash Flow | 0 | 0 | -0 | 1 | 24 |
| Free Cash Flow | -1 | -4 | -5 | -6 | -1 |
| CFO/OP | 36% | -101% | -66% | -63% | -9% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 23 | 87 | 142 | 60 | 128 |
| Inventory Days | 5 | 103 | 161 | 150 | 191 |
| Days Payable | 12 | 40 | 48 | 8 | 80 |
| Cash Conversion Cycle | 16 | 149 | 255 | 202 | 239 |
| Working Capital Days | -3 | 76 | 185 | 180 | 221 |
| ROCE % | 52% | 38% | 34% | 25% |
Documents
Announcements
-
Results - Financial Results For The Half Year And Year Ended March 31 2026
28 May - Board approved FY26 audited standalone results, unmodified audit opinion, and IPO proceeds utilization on May 28, 2026.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E On May 28 2026
28 May - Board approved FY26 audited standalone results; profit rose to INR 1,303.29 lakh; IPO proceeds utilized INR 509.15 lakh.
-
Board Meeting Intimation for Meeting Of Board Of Speciality Medicines Limited To Be Held On May 28 2026
21 May - Board meets May 28, 2026 to approve FY26 audited standalone results; trading window closed from April 1, 2026.
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 19 May
-
Intimation Of Contact Details Of Key Managerial Personnel Pursuant To Regulation 30(5) Of SEBI (LODR) Regulations 2015
28 Apr - Company disclosed KMP contact details for Regulation 30(5) and uploaded them on website.
Business Profile[1]
Co. is engaged in the marketing and distribution of specialty pharmaceutical formulations, with a focus on high-cost oral and injectable drugs across key therapeutic areas including oncology, immunology, neurology, and rare diseases.